Reporting from the ESMO Virtual Congress 2020, Yelena Janjigian comments on practice changing results with first-line immune checkpoint inhibitor plus chemotherapy in advanced gastric, gastro-oesophageal junction or oesophageal cancers. She details results that are both, clinically meaningful and statistically significant in terms of progression-free and overall survival, while there were no new signals regarding tolerance.
- LBA6_PR - Nivolumab (NIVO) Plus Chemotherapy (CT) Versus CT in First-Line (1L) Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): First Results of the CheckMate 649 Study
- LBA7_PR - Nivolumab with chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric or gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
- LBA8_PR - Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study
This video was supported with grants from Daiichi Sankyo and Roche